| Formulation |
The PARK2 solution (1mg/ml) contains 20mM Tris-HCl buffer (pH 8.0), 0.4M Urea and 10% glycerol. |
| Purity |
Greater than 80% as determined by SDS-PAGE. |
| Description |
PARK2 Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 485 amino acids (1-465) and having a molecular mass of 53.8 kDa. PARK2 is fused to a 20 amino acid His-tag at N-terminus. |
| Protein Background |
PARK2 is an element in a multiprotein E3 ubiquitin ligase complex which mediates the targeting of substrate proteins for proteasomal degradation. PARK2 alterations can result in Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing creates multiple transcript variants encoding distinct isoforms. |
| Expression host |
Escherichia Coli. |
| Synonyms |
Parkin RBR E3 Ubiquitin Protein Ligase, Parkinson Juvenile Disease Protein 2, Parkinson Protein 2 E3 Ubiquitin Protein Ligase (Parkin), Parkinson Disease (Autosomal Recessive, Juvenile) 2 Parkin, PRKN, AR-JP, PDJ, E3 Ubiquitin Ligase, LPRS2, EC 6.3.2.-. |
| Reagent Appearance |
Sterile Filtered clear solution. |
| Stability |
Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles. |
| Amino acid sequence |
MGSSHHHHHH SSGLVPRGSH MIVFVRFNSS HGFPVEVDSD TSIFQLKEVV AKRQGVPADQ LRVIFAGKEL RNDWTVQNCD LDQQSIVHIV QRPWRKGQEM NATGGDDPRN AAGGCEREPQ SLTRVDLSSS VLPGDSVGLA VILHTDSRKD SPPAGSPAGR SIYNSFYVYC KGPCQRVQPG KLRVQCSTCR QATLTLTQGP SCWDDVLIPN RMSGECQSPH CPGTSAEFFF KCGAHPTSDK ETSVALHLIA TNSRNITCIT CTDVRSPVLV FQCNSRHVIC LDCFHLYCVT RLNDRQFVHD PQLGYSLPCV AGCPNSLIKE LHHFRILGEE QYNRYQQYGA EECVLQMGGV LCPRPGCGAG LLPEPDQRKV TCEGGNGLGC GFAFCRECKE AYHEGECSAV FEASGTTTQA YRVDERAAEQ ARWEAASKET IKKTTKPCPR CHVPVEKNGG CMHMKCPQPQ CRLEWCWNCG CEWNRVCMGD HWFDV |
